Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
AEON
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.24
N/A
-20.14
vs -0.80
Q2.24
N/A
-11.51
vs -40.37
Q3.24
N/A
-11.51
vs NA
Q4.24
N/A
3.75
vs NA
Q1.25
N/A
-0.19
vs -20.14
Sales Growth
YoY
Current
Estimates
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Return on Equity
QoQ
Q4.22
+12%
0.12
vs NA
Q1.23
NA
NA
vs 0.12
Q2.23
NA
NA
vs NA
Q3.23
NA
NA
vs NA
Q1.24
+59%
0.59
vs NA
Q2.24
-587%
-5.87
vs 0.59
Q3.24
+19%
0.19
vs -5.87
Q4.24
-7%
-0.07
vs 0.19
Institutionnal Ownership
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Quote Panel
Key Metrics
Relative Strength
AEON
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.01 ( 1.40%)
Pre-market 0.51$0.01 (2.50%)
Relative Strenght
98
Volume Buzz
-74%
Earning Acce
No
Dist 52w H.
100%Forecast
NaN%2025-Revenue
NaN%2025-EPS
113%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How AEON compares to sector?
AEON
0x